Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Zsuzsanna Bago-Horvath; Margaretha Rudas; Peter Dubsky; Raimund Jakesz; Christian F Singer; Ralf Kemmerling; Richard Greil; Andrea Jelen; Gerhard Böhm; Zerina Jasarevic; Anton Haid; Christine Gruber; Sabine Pöstlberger; Martin Filipits; Michael Gnant

doi:10.1158/1078-0432.CCR-11-1846

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Zsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, Raimund Jakesz, Christian F Singer, Ralf Kemmerling, Richard Greil (Co-author), Andrea Jelen, Gerhard Böhm, Zerina Jasarevic, Anton Haid, Christine Gruber, Sabine Pöstlberger, Martin Filipits, Michael Gnant

Institute of Pathology
Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

13 Citations (Web of Science)

Original language	English
Pages (from-to)	7828-7834
Journal	CLINICAL CANCER RESEARCH
Volume	17
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-11-1846
Publication status	Published - 2011

Keywords

ESTROGEN-RECEPTOR
ENDOCRINE THERAPY
PROGNOSTIC MARKER
KI-67 EXPRESSION
PREDICTIVE-VALUE
KI67 EXPRESSION
LABELING INDEX
TRIAL
CHEMOTHERAPY
CARCINOMA

Access to Document

10.1158/1078-0432.CCR-11-1846

Cite this

Bago-Horvath, Z., Rudas, M., Dubsky, P., Jakesz, R., Singer, C. F., Kemmerling, R., Greil, R., Jelen, A., Böhm, G., Jasarevic, Z., Haid, A., Gruber, C., Pöstlberger, S., Filipits, M., & Gnant, M. (2011). Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. CLINICAL CANCER RESEARCH , 17(24), 7828-7834. https://doi.org/10.1158/1078-0432.CCR-11-1846

Bago-Horvath, Zsuzsanna ; Rudas, Margaretha ; Dubsky, Peter et al. / Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. In: CLINICAL CANCER RESEARCH 2011 ; Vol. 17, No. 24. pp. 7828-7834.

@article{2623f245baac43a19821f07715c7f683,

title = "Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer",

keywords = "ESTROGEN-RECEPTOR, ENDOCRINE THERAPY, PROGNOSTIC MARKER, KI-67 EXPRESSION, PREDICTIVE-VALUE, KI67 EXPRESSION, LABELING INDEX, TRIAL, CHEMOTHERAPY, CARCINOMA",

author = "Zsuzsanna Bago-Horvath and Margaretha Rudas and Peter Dubsky and Raimund Jakesz and Singer, {Christian F} and Ralf Kemmerling and Richard Greil and Andrea Jelen and Gerhard B{\"o}hm and Zerina Jasarevic and Anton Haid and Christine Gruber and Sabine P{\"o}stlberger and Martin Filipits and Michael Gnant",

note = " Paracelsus Private Med Univ, Gen Hosp Salzburg, Dept Internal Med 3, Salzburg, Austria",

year = "2011",

doi = "10.1158/1078-0432.CCR-11-1846",

language = "English",

volume = "17",

pages = "7828--7834",

journal = "CLINICAL CANCER RESEARCH ",

issn = "1078-0432",

publisher = "Amer Assoc Cancer Research",

number = "24",

}

Bago-Horvath, Z, Rudas, M, Dubsky, P, Jakesz, R, Singer, CF, Kemmerling, R, Greil, R, Jelen, A, Böhm, G, Jasarevic, Z, Haid, A, Gruber, C, Pöstlberger, S, Filipits, M & Gnant, M 2011, 'Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer', CLINICAL CANCER RESEARCH , vol. 17, no. 24, pp. 7828-7834. https://doi.org/10.1158/1078-0432.CCR-11-1846

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. / Bago-Horvath, Zsuzsanna; Rudas, Margaretha; Dubsky, Peter et al.
In: CLINICAL CANCER RESEARCH , Vol. 17, No. 24, 2011, p. 7828-7834.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

AU - Bago-Horvath, Zsuzsanna

AU - Rudas, Margaretha

AU - Dubsky, Peter

AU - Jakesz, Raimund

AU - Singer, Christian F

AU - Kemmerling, Ralf

AU - Greil, Richard

AU - Jelen, Andrea

AU - Böhm, Gerhard

AU - Jasarevic, Zerina

AU - Haid, Anton

AU - Gruber, Christine

AU - Pöstlberger, Sabine

AU - Filipits, Martin

AU - Gnant, Michael

N1 - Paracelsus Private Med Univ, Gen Hosp Salzburg, Dept Internal Med 3, Salzburg, Austria

PY - 2011

Y1 - 2011

KW - ESTROGEN-RECEPTOR

KW - ENDOCRINE THERAPY

KW - PROGNOSTIC MARKER

KW - KI-67 EXPRESSION

KW - PREDICTIVE-VALUE

KW - KI67 EXPRESSION

KW - LABELING INDEX

KW - TRIAL

KW - CHEMOTHERAPY

KW - CARCINOMA

U2 - 10.1158/1078-0432.CCR-11-1846

DO - 10.1158/1078-0432.CCR-11-1846

M3 - Original Article

C2 - 21998336

SN - 1078-0432

VL - 17

SP - 7828

EP - 7834

JO - CLINICAL CANCER RESEARCH

JF - CLINICAL CANCER RESEARCH

IS - 24

ER -

Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R et al. Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. CLINICAL CANCER RESEARCH . 2011;17(24):7828-7834. doi: 10.1158/1078-0432.CCR-11-1846